Seminar “Digital nation. Personalized solutions for healthcare & wellbeing”
Date: January 31, 2022 at 12:30–17:30
Venue: e-Estonia Pavilion MR-01 EXPO 2020
Partner: City of Tartu (Estonia) and Antegenes
Moderators: Dr. Mazin Gadir (UAE), Dr. Peeter Padrik and Prof. Andres Salumets (Estonia)
- International healthcare delegations in EXPO Health & Wellness Week
- Leaders of United Arab Emirates healthcare authorities and healthcare services providers
- Leaders of Dubai, Abu Dhabi, Saudi Arabia, Qatar biobanks
- Participants in EXPO Health & Wellness Week
- Investment fund representatives
World-leading, digital nation Estonia is setting out to relieve the burden of the dramatic global increase in the prevalence of various illnesses through innovating the healthcare ecosystem. Estonia has been one of the most successful nations globally in doing this, and it has managed to create and integrate its own genomics-based solutions into routine healthcare.
Come and learn how high-level research has given rise to globally successful life-science companies. Examples of the contributions of these companies, including in global COVID-19 molecular diagnostics, and in precision genetics solutions in various clinical fields, from clinical and pharmacogenetics, digital therapeutics to assisted reproduction and screening of pregnancies for healthy offspring, will be given.
The seminar panelists are leading figures who can potentially be your partners in research, innovation and healthcare, to help cover patients’ entire lifespans, from conception to advanced age.
Meet the future of health and care in the Estonian pavilion!
Estonia was one of the very first nations to launch a population-based biobank. Since then, public trust toward genetics and expectation of personalized medicine solutions have skyrocketed. Today, the first applications are finally reaching the public. Implementing personalized medicine is difficult because it requires involvement of key players along the whole value chain and consideration of ethical, legal and societal implications. In his vision speech, Prof. Metspalu explains the success story of Estonian Health Tech.
Introduction by H.E. Mr Jaan Reinhold – Ambassador of the Republic of Estonia to the United Arab Emirates
Vision speech about Estonia’s success from Biobank to Personalized Medicine by Prof. Mait Metspalu – PhD, Head of the Institute of Genomics, University of Tartu.
More personalized and efficient cancer prevention can help us avoid millions of cancer deaths. Antegenes introduces innovative solutions and programs for genetics-based, personalized cancer prevention and screening. Estonia is one of the first countries in the world to have implemented these innovations in the healthcare system. Join us as we introduce how our novel technology can help people live longer and healthier lives. Join us to discuss the topics associated with developments in this field, and create partnerships to develop and implement personalized cancer prevention locally and worldwide.
Dr. Peeter Padrik – MD, PhD – Founder & CEO Antegenes, Estonia: “Genetics based personalized cancer prevention”
Dr. James Mackay – MA, MD, FRCP, FRCPE, United Kingdom: “Genetics based personalized cancer prevention activities in the United Kingdom”
Dr. Fatima Alkaabi – Director of the Genome office in Abu Dhabi Executive Office: “My Genes. My Health. Patient’s Journey to Healthier Future”
Moderated by Dr. Peeter Padrik – Founder & CEO of Antegenes. Associate Professor of Oncology at Tartu University Hospital.
Estonian evidence-based digital health technology founders open up a discussion on how healthcare transformation, preventive and human-empowerment-based digital technologies can facilitate high-value healthcare. Also, they bring to light how scientifically controlled solutions help real people – sharing examples from gamifying fighting children’s mental health problems to helping adults learn to live with their life-long diseases.
- How digital transformation of healthcare enables more human-centric and value-based healthcare?
- How real-time data will facilitate for better preventive and better quality care?
- How to empower mental health solutions through novel technological approach?
- How digital health makes care more accessible?
- Bringing Estonia’s top digital healthcare success to the Middle East market.
- Mental health has been one of the most neglected areas of public health, see how Estonia is setting a global example in developing technology to improve mental health in a scalable way.
Moderated by Dr. Mazin Gadir
Four top experts in the field discuss working solutions and case studies in tackling the challenges in modern molecular diagnostics. Solutions will be brought to you from various fields, such as screening, NGS- and PCR-based testing.
- Successful interplay between laboratory medicine, genomic knowledge, and modern technology to implement molecular diagnostics as complexity of the detecting of genomic variants, diagnosing and prognosing diseases, and monitoring response to therapy.
- Lessons from COViD19, laboratory perspective.Don’t be afraid, testing has helped us to overcome and handle risks.
- Precision medicine gives a hand in daily matters by using our genetic information and translating that via data-intensive analysis to help each of us individually. We are able to solve which medical drugs might help, suggesting early prevention to stay healthy for longer years.
- Several options for families to have their child even when family forming is delayed.
Prof. Andres Salumets – Member of the board of Competence Centre on Health Technologies (Research and product development in personal medicine, drug development and both human and veterinary reproductive medicine)
Moderated by Prof. Andres Salumets
Meet and greet the best of Estonian innovative companies and experience the most digitally advanced healthcare in the world:
- Asper Biogene
- Competence Centre on Health Technologies
- The Institute of Genomics, University of Tartu
- Triumf Health
- Solis Biodyne
Also, representatives of supporting organizations for networking:
Meet our panelists:
Professor of evolutionary genomics who completed his PhD in population genetics at the University of Tartu 2006. From 2012 to 2013, Prof. Metspalu was a visiting research fellow at UC Berkeley. His research concentrates on using and developing population genetics approaches (incl. ancient DNA) to understand the genetic diversity and adaptations of humans through time.
Prof. Mait Metspalu is the director of the Institute of Genomics at the University of Tartu, which houses the population-based Estonian Biobank. He is involved in facilitating the transfer of knowledge of genetic disease risks into the Estonian medical system.
Director of partnerships, bid management and client relationships at IQVIA Payer Provider Government Management Consultancy. He is also an external advisor at the Executive Office for Organizational Transformation, Dubai Health Authority and is responsible for health strategy development, implementation, execution and transformation.
Founder and CEO of Antegenes. associate professor of oncology at University of Tartu Hospital. Dr. Padrik has 30 years of experience as a clinician, researcher, leader, and healthcare manager, working previously as the head of the Hematology & Oncology Clinic and as director of the Cancer Center at University of Tartu Hospital.
He is a pioneer in the implementation of innovative genetic information in healthcare. Dr. Padrik’s vision and aim is to achieve longer life for people by implementing genetics-based, personalized precision prevention of common complex diseases like cancers and cardiovascular and metabolic diseases.
Dr Fatima Alkaabi is the Director of the UAE Genomic Council at Abu Dhabi Executive Office and Executive Director of the Abu Dhabi-Bone Marrow Transplant program at Abu Dhabi Stem Cell Center (ADSCC). She brings over 14 years of experience and has previously served as the Head of Hematology and Oncology as well as the Acting Deputy Chief Medical Officer at Sheikh Khalifa Medical City (SKMC).
She graduated from the UAE University’s Faculty of Medicine & Health Sciences, earning her M.B.B.S. credential before obtaining her Master of Public Health (MPH) from the Bloomberg School of Public Health at John Hopkins University. Dr Fatima has an MSc Cancer from University College London (UCL) and a Fellowship in Hematology and BMT at Royal Free Hospital (NHS).
Dr James Mackay has been practicing as a Consultant Genetic Oncologist for over 25 years within the NHS and private sector in the UK, advising cancer patients and their families on genetic testing.
Dr Mackay was one of the first accredited Consultant Clinical Genetic Oncologists with a special interest in cancer genetics in the UK and is an honorary senior lecturer in the Research Department of Oncology, the Cancer Institute, University College London. He has been involved in clinical academic projects throughout his career. His clinical interests are cancer genetics, inherited cancer, cancer screening and the introduction of tumour genetic tests into clinical cancer care.
Dr Mackay trained as a consultant medical oncologist with a special interest in cancer genetics at Trinity College Cambridge and the University of Edinburgh Medical School.
Member of the board of the Competence Centre on Health Technologies. He is an Estonian biologist and biochemist and is currently professor of reproductive medicine at the University of Tartu (Estonia) and Karolinska Institutet (Sweden). Prof. Salumets was a member of the Executive Committee of the European Society of Human Reproduction and Embryology and has a significant number of publications in several scientific journals.
Founder and CEO of Documental. He is professor of psychopharmacology at the University of Tartu, visiting professor at the Faculty of Medicine, Imperial College London and member of the Scientific Advisory Board of the Estonian Genome Centre. His clinical experience in psychiatry spans 16 years, 5 of which were spent as consultant for the admissions ward at Hammersmith and Fulham Mental Health Unit on the Charing Cross Hospital site of West London Mental Health NHS Trust.
Dr. Maron is the author of more than 60 scientific publications and 4 book chapters in the field of psychiatry. He is also a frequent speaker and chairman at international congresses and meetings. In 2011 he was awarded the Estonian National Science Award in Medicine.
Founder and CEO of Triumf Health. Triumf Health has developed an evidence-based digital therapeutics platform for children in order to deliver personalized psychological support through a game environment. Dr. Haljas has been advocating the importance of implementing mental-health innovations for years in Estonia. She is also the founder of the Mental Health Innovation Hub, a global center for excellence that is headquartered in Estonia.
Co-founder of Migrevention, she is a health founder who has experienced migraines for 15 years, and she has a mission to improve the life quality of fellow patients. In 2020 she founded Migrevention, a digital headache clinic, together with top medical experts from Estonia. Now she uses her knowledge and pain for the benefit of others by making evidence-based migraine treatment accessible for everyone and everywhere. Ms. Laks is also a keen patient advocate, and founding member and spokesperson for the Estonian Migraine and Headache Patients Association.
CEO of Solis BioDyne. As a visionary leader, he has more than 19 years of background and experience in the Pharma and Biotech markets. Before joining Solis BioDyne, Mr. Goldenbaum worked with QIAGEN, BioMerieux and Eppendorf in Asia-Pacific and Europe. With extensive knowledge in the field, he implements proven solutions to today’s biotech challenges.
CEO of Asper Biogene, is an Estonian entrepreneur from the field of research-intensive business, including genetics, health technologies etc. Using his extensive experience from working with different industries, he contributes as a leader to several multi-actor research institutions and collaborative projects. Over the last decade he has also been Estonia’s expert and representative in the European Committee for Standardization (CEN).